Radiopharmaceuticals Market to Reach $8,207 Million, by 2022

According to a new report published by Allied Market Research, titled, Global Radiopharmaceuticals Market”, the radiopharmaceuticals market is expected to generate revenue of $8,207 million by 2022. The diagnostics segment held a dominant share in the world radiopharmaceuticals market in 2015, and is expected to maintain its lead during the forecast period. Asia-Pacific is projected to continue to dominate the market throughout the forecast period.

The world radiopharmaceuticals market is poised to grow at a significant pace, owing to growing demand for non-invasive techniques, availability of effective cancer treatment, and ability to observe the functioning of the organ from outside the body. Furthermore, increasing incidence of cancer & cardiovascular aliments, growing demand for alpha radio immunotherapy-based targeted cancer treatment, mounting call for nuclear imaging techniques, and advancements in radiotracers are expected to open new avenues in the world radiopharmaceuticals market. Factors that are expected to drive the use of radiopharmaceuticals include changing lifestyle, elevated levels of stress, and ability to identify various diseases sooner than other diagnostic tests. However, factors such as supply volatility & logistical challenges, stringent regulatory vigil, and competition from conventional diagnostic procedures are anticipated to impede the market growth.

Read more details of the report at:

The oncology segment contributed more than half of the market share in the overall radiopharmaceuticals market in 2015 and is expected to continue the same trend owing to perpetual rise in the number of cancer cases. The SPECT modality segment dominated the radiopharmaceuticals market in 2015, whereas the PET modality segment is anticipated to grow at a comparatively higher CAGR of 8.3% from 2016 to 2022. PET segment is driven by better quality of image and higher precision in diagnosis. Other reasons attributed to its sustained dominance are growing R&D activities especially in developing economies and widening scope of radiopharmaceutical applications such as thyroid, oncology, and bone pain palliation.

Key findings of the study:

  • Therapeutics segment is projected to be the fastest growing segment in the world radiopharmaceuticals market, registering a CAGR of 16.9% from 2016 to 2022.
  • SPECT modality segment is expected to dominate the world radiopharmaceuticals market in 2015 and expected to retain its position throughout the study period.
  • Thyroid application segment is expected to exhibit double-digit CAGR of 11%.
  • Oncology application segment is expected to continue to lead the world radiopharmaceuticals market, accounting for close to 60% share by 2022.
  • Asia-Pacific is projected to be the fastest growing radiopharmaceuticals market, registering a CAGR of 8.4%.

The Asia-Pacific radiopharmaceuticals market is expected to offer lucrative growth opportunities during the forecast period owing to aging population and increasing cancer incidences. The leading Asia-Pacific countries, such as China, Japan, and Australia would exhibit a steady growth rate. The key companies profiled in the report are Mallinckrodt plc., General Electric, Medtronic Inc., Bayer AG, Cardinal Health Inc., Lantheus Medical Imaging, Inc., IBA Group, Bracco Imaging S.p.A., and NTP Radioisotopes SOC Ltd.